202 related articles for article (PubMed ID: 27779157)
1. Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients.
Zhang W; Zhang Q; Zheng TT; Zhen JC; Niu XH
Chin Med J (Engl); 2016 Nov; 129(21):2530-2534. PubMed ID: 27779157
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
3. Delayed methotrexate clearance in osteosarcoma patients treated with multiagent regimens of neoadjuvant chemotherapy.
Bacci G; Ferrari S; Longhi A; Forni C; Loro L; Beghelli C; Tremosini M; Versari M
Oncol Rep; 2003; 10(4):851-7. PubMed ID: 12792734
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy.
Dupuis C; Mercier C; Yang C; Monjanel-Mouterde S; Ciccolini J; Fanciullino R; Pourroy B; Deville JL; Duffaud F; Bagarry-Liegey D; Durand A; Iliadis A; Favre R
Anticancer Drugs; 2008 Mar; 19(3):267-73. PubMed ID: 18510172
[TBL] [Abstract][Full Text] [Related]
5. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
[TBL] [Abstract][Full Text] [Related]
7. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
8. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.
Pignon T; Lacarelle B; Duffaud F; Guillet P; Catalin J; Durand A; Monjanel S; Favre R
Cancer Chemother Pharmacol; 1994; 33(5):420-4. PubMed ID: 8306417
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate for osteosarcoma: toxicity and clinical results.
Breithaupt H; Küenzlen E
Oncology; 1983; 40(2):85-9. PubMed ID: 6600827
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs.
Bacci G; Ferrari S; Picci P; Zolezzi C; Gherlinzoni F; Iantorno D; Cazzola A
J Chemother; 1996 Dec; 8(6):472-8. PubMed ID: 8981189
[TBL] [Abstract][Full Text] [Related]
12. Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections.
Wright KD; Panetta JC; Onar-Thomas A; Reddick WE; Patay Z; Qaddoumi I; Broniscer A; Robinson G; Boop FA; Klimo P; Ward D; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 2015 Jan; 75(1):27-35. PubMed ID: 25342291
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
[TBL] [Abstract][Full Text] [Related]
14. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
15. [The effect of methotrexate pharmacokinetics and of leucovorin rescue on the prognosis of osteosarcoma].
Graf N; Jost W; Müller J; Keller HE; Sitzmann FC
Klin Padiatr; 1990; 202(5):340-6. PubMed ID: 2214594
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
[TBL] [Abstract][Full Text] [Related]
20. Risk Factors for Delayed Elimination of Methotrexate in Children, Adolescents and Young Adults With Osteosarcoma.
Misaka KO; Suga Y; Staub Y; Tsubata A; Shimada T; Sai Y; Matsushita R
In Vivo; 2020; 34(6):3459-3465. PubMed ID: 33144454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
